Thyroid Eye Disease Market Expands With Targeted Treatments and Diagnostic Advances

 

Thyroid Eye Disease Market Overview and Growing Clinical Awareness

Thyroid Eye Disease (TED) is an autoimmune disorder that affects tissues around the eyes and is primarily linked to Graves’ disease. Symptoms may include inflammation, eyelid retraction, dryness, double vision, swelling, and proptosis, with severe cases potentially threatening eyesight. The thyroid eye disease market is gaining momentum as awareness, diagnostic capabilities, and targeted treatment options improve across the United States, EU4, the United Kingdom, and Japan.

Thyroid Eye Disease Treatment Market Benefits From Rising Patient Identification

Growing recognition of TED is creating opportunities within the thyroid eye disease treatment market. DelveInsight estimates that approximately 2.386 million people across the seven major markets had TED in 2022. The United States represented around 42% of these cases, followed by Germany and Japan. Women accounted for approximately 80% of diagnosed prevalent cases.

Because symptoms can vary considerably, mild, unilateral, euthyroid, and atypical presentations may remain undetected. Improved clinical awareness and greater collaboration between ophthalmologists and endocrinologists could therefore increase diagnosis and treatment rates.

Hashimotos Disease Market and Thyroid Eye Disease Diagnostic Landscape

Diagnosis typically combines clinical examination with thyroid-related laboratory testing and orbital imaging. Measurements of thyroid-stimulating antibodies can support diagnosis, while CT or MRI may help evaluate orbital abnormalities and rule out other conditions.

The relationship between TED and autoimmune thyroid disorders also creates relevance for companies assessing the hashimotos disease market. Although Graves’ disease has the strongest association with TED, broader thyroid autoimmunity remains an important consideration when evaluating patients with ocular symptoms.

US Thyroid Disorder Market Strengthened by Targeted Therapies

The therapeutic landscape has changed significantly with the emergence of targeted biologics. Historically, physicians relied on corticosteroids, immunosuppressants, orbital radiation, and selected off-label biologic treatments for moderate-to-severe active disease. The introduction of TEPEZZA (teprotumumab) marked a major advancement by targeting IGF-1R and addressing important manifestations such as proptosis and diplopia.

These developments are contributing to growth in the us thyroid disorder market, while encouraging pharmaceutical companies to investigate alternative biological mechanisms and more convenient administration methods.

Exophthalmos Treatment Market Faces Unmet Needs

Patients experiencing prominent eye bulging continue to have substantial functional and cosmetic concerns. The exophthalmos treatment market therefore extends beyond controlling inflammation to addressing persistent structural changes. Orbital decompression and reconstructive surgery can be considered for selected patients, although surgical approaches may carry risks and do not necessarily control active inflammation.

Similarly, the bulging eye treatment market is influenced by demand for therapies that can deliver meaningful improvements in appearance and visual function while reducing the burden associated with invasive procedures.

Thyroid Eye Disease Market Pipeline Creates Competitive Opportunities

The developing pipeline is introducing therapies with mechanisms beyond conventional immunosuppression. Batoclimab, an FcRn-targeting antibody developed by Immunovant, is being evaluated as a potential treatment that could reduce pathogenic IgG antibodies while offering subcutaneous administration.

Viridian Therapeutics’ VRDN-001, or veligrotug, represents another notable candidate targeting IGF-1R. The FDA granted Breakthrough Therapy Designation to veligrotug for TED in May 2025, highlighting its potential role in future treatment strategies.

Novartis is also exploring cosentyx thyroid eye disease, with secukinumab providing an approach based on a different inflammatory pathway. Increasing mechanistic diversity could expand treatment choices and intensify competition.

Conclusion

TED management is shifting toward earlier diagnosis and more precise therapeutic strategies. Expanding disease awareness, improved diagnostic approaches, and continued development of biologic therapies are expected to address significant unmet needs. As clinical research advances and treatment choices diversify, collaboration among specialists and continued innovation will remain essential to improving outcomes and quality of life for individuals affected by this autoimmune eye disorder.

Latest Reports by DelveInsight:

uk healthcare report, varicose vein market, antibody drug conjugate market, bone grafts and substitutes market, chemotherapy induced anemia market, hypoventilation market, paget's disease market, stem cell market, vascular grafts market, celiac disease market, dental implants and prosthesis market, diabetic retinopathy market, dilators market, eisenmenger complex market, endoscopic ultrasound market, erectile dysfunction market, exophthalmos market, mrna based vaccines and therapeutics market, spinal cord stimulators market, von willebrand disease market, aesthetic implants market, biliary tumor market, catheter stabilization devices market, compartment syndrome market, donohue syndrome market, fibrocystic breast condition market, hearing implants market

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com